Alice Wei, MD, CM, MSc, FRCSC, FACS
Hepatopancreatobiliary Surgeon
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Disease of the Liver, Bile Ducts, Gallbladder, and Pancreas
- Pancreatic Cancer
- Pancreatic Cysts
Meet MSK Surgeon Alice Wei
Request an Appointment
About Me
- Co-Director, Surgical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research
- Associate Professor of Sugery, Weill-Cornell School of Medicine
I am a surgeon who specializes in treating diseases of the liver, bile duct, gallbladder, and pancreas.
I have special expertise in advanced minimally invasive techniques, which includes robotic liver and pancreas surgery. These techniques help my patients recover more quickly. I also perform ablation therapy. This uses special needles to apply heat, cold, lasers, or chemicals to destroy cancer cells. I am proud to be part of a multidisciplinary team that provides outstanding care to people with cancer.
Read more
Before coming to MSK, I worked at a leading cancer center in Canada. I was one of the most experienced surgeons in the country treating hepatobiliary cancers and I consider it a privilege to help people through a very difficult time in their life. When it comes to cancer care, the best treatment is specific to that person. It is incredibly meaningful to guide people through treatment, to help them determine which of the established or perhaps new treatments is best suited to them.
The patients I see often feel anxiety from fear of the unknown. I think the best way to reassure them is to be as knowledgeable as possible about their condition so they can feel confident they are receiving the best possible treatment for their disease.
I make sure to spend time answering any questions patients may have about what the future will hold. I like to ask people at the end of the visit, “Is that what you expected to hear from me?” This gives them a chance to tell me what they were thinking before they came. When they finish treatment, I hope they feel that they received the best care for their situation.
In addition to caring for patients, I conduct research on ways to make cancer surgery even more effective. I have helped develop strategies to improve the quality of care for people after complex surgery. I have also advised on health policies to guide doctors and to provide policymakers with the most up-to-date cancer knowledge.
In my spare time, I spend as much time as possible enjoying the company of my husband and kids.
A hepatopancreatobiliary (heh-PA-toh-PAN-kree-A-to-BIH-lee-AYR-ee) surgeon is a doctor with special training in surgery on the liver, pancreas, gallbladder, and bile ducts. They are also called an HPB surgeon.
My Specialties
- Disease of the Liver, Bile Ducts, Gallbladder, and Pancreas
- Pancreatic Cancer
- Pancreatic Cysts
- Liver Cancer
- Bile Duct Cancer
- Gallbladder Cancer
- Liver Metastases
- Gastrointestinal Neuroendocrine Tumors
- Ablation Therapy
- Robotic Procedures
Education
- MD CM, McGill University
- MSc, Cell Biology, University of Toronto
- MSc, Clinical Epidemiology, University of Toronto
Residencies
- General Surgery – University of Toronto
Fellowships
- Hepatobiliary and GI Transplantation – Toronto General Hospital, University of Toronto
Board Certifications
- Surgery (US)
- General Surgery (Canada)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, HMO
MSK has a tentative agreement with Cigna to continue coverage in 2024.
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Wei sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Wei
- A Phase 2 Study of NALIRIFOX Plus Radiation Therapy to Treat Pancreatic Cancer
- Clinical Trials Co-Investigated by Dr. Wei
- A Phase 3 Study Assessing the Addition of Local Therapies to the Usual Chemotherapy for Limited Metastatic Colorectal Cancer: The ERASur Study
- A Phase III Study of Chemotherapy After Surgery versus Chemotherapy Before and After Surgery for Operable Pancreatic Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, De Fiore F, Cripps X, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux J-L, Juzyna B, Eng S, O’’Callaghan C, Jouffroy C, Rat P, Malka D, Castan F, Bachet J-B. FOLFIRINOX versus Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379:2395-2406.
Wei AC, Coburn NG, Devitt KS, Serrano PE, Moulton CA, Cleary SP, Law C, Moore MJ, Gallinger S. Survival Following Resection of Intra- and Extra-Hepatic Metastases from Colorectal Cancer: A Phase II Trial. Ann Surg Oncol. 2016;23(8):2644-51.
Read more
Serrano PE, Herman JM, Griffith KA, Zalupski MM, Kim EJ, Bekaii-Saab TS, Ben-Josef E, Dawson LA, Ringash J, Wei AC. Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;90(2):270-7.
Wei AC, Sandhu L, Devitt KS, Gagliardi AR, Kennedy ED, Urbach DR, Gallinger S, Baxter NN. Practice patterns for the management of hepatic metastases from colorectal cancer: a mixed methods analysis. Ann Surg Oncol. 2013;20(5):1567-74
Visit PubMed for a full listing of Dr. Wei’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alice Wei discloses the following relationships and financial interests:
-
HistoSonics, Inc.
Professional Services and Activities
-
Ipsen Pharma
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
